Cardio-vascular
Refine Search
Pharmaceutical
Mineralys Therapeutics, a previously private company in the portfolio of HBM Healthcare Investments, successfully completed its IPO last Friday. 13 February 2023
Pharmaceutical
Britain’s AstraZeneca has secured a new European approval for heart med Forxiga (dapagliflozin), an innovative medicine known in the USA as Farxiga. 8 February 2023
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued draft guidance, saying that it has not recommended the diabetes drug Jardiance (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction for use on the National Health Service (NHS). 8 February 2023
Biotechnology
The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) to expand the use of Takhzyro (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients aged two to 6 February 2023
Pharmaceutical
Swiss pharma company Idorsia was trading 10% lower at lunchtime on Monday. 6 February 2023
Pharmaceutical
French privately-held pharma company Servier has announced its financial results for the 2021/22 financial year, highlighting the major steps of its ongoing transformation. 3 February 2023
Pharmaceutical
US drugmaker Bristol Myers Squibb was trading 2% higher at lunchtime Thursday after presenting its fourth quarter and full year 2022 financial results. 2 February 2023
Pharmaceutical
Swiss pharma giant Novartis presented its financial results for the fourth quarter and 2022 as a whole on Wednesday morning. 1 February 2023
Biotechnology
US biotech giant Amgen released mixed financial results for the fourth quarter and full year 2022 versus comparable periods in 2021, after markets closed on Monday. 1 February 2023
Pharmaceutical
US drugmaker Pfizer cemented its place at the top of the pile of global pharma companies in delivering its 2022 financial results. 31 January 2023
Pharmaceutical
In a sudden turn of events, Novartis' Entresto (sacubitril/valsartan) patent has been reinstated in India, after a two-judge bench stayed a previous order that invalidated it. 24 January 2023
Generics
As a blockbuster heart failure drug by Swiss pharma giant Novartis goes off-patent, several Indian drug majors are rushing to market with their generic applications. The patent loss of Entresto (sacubitril/valsartan) has brought on significant disruptions in India’s cardiology sector. High courtroom drama ensued a few days before the patent loss and had everyone on tenterhooks, reports The Pharma Letter’s India correspondent. 20 January 2023
Biotechnology
California, USA-based clinical-stage biopharmaceutical company 89bio’s pegazofermin has potential to become one of the major players in the dyslipidemia space if it is successful in Phase III clinical trials, says analyst. 17 January 2023
Pharmaceutical
The cardiomyopathies market in the 68 major world markets (68M) is set to grow from $3.07 billion in 2021 to $9.63 billion in 2031 at a compound annual growth rate (CAGR) of 12.1%. 16 January 2023
Biotechnology
The past week kicked off with several M&A deals being announced. The largest of these was by UK pharma major AstraZeneca revealing that is acquiring CinCor Pharma for up to $1.8 billion, with the aim of expanding it cardiorenal portfolio and pipeline as well as blood pressure drug baxdrostat. Also, French drugmaker Ipsen announced a takeover bid for USA-based Albireo in a deal worth almost $1 billion, bringing with it rights to liver disease drug Bylvay. Arecor Therapeutics reached a key milestone in the development of the ready-to-use injectable AT307 in its partnership with Hikma Pharmaceuticals but the latter also returned rights to another candidate, AT282. Privately-held US mRNA specialist Anima Biotech entered into a collaboration with US pharma major AbbVie to develop cancer and immune disorder therapies. 15 January 2023
Biotechnology
US neuromuscular and cardiac diseases specialist Solid Biosciences and privately-held Dutch biotech Phlox Therapeutics have announced a strategic collaboration focused on genetic cardiac diseases. 12 January 2023
Pharmaceutical
Research from industry analyst GlobalData finds that western companies are likely to play an important role in providing new cardiovascular disease (CVD) management options in China. 12 January 2023
Pharmaceutical
Presentations from German group Bayer at the JP Morgan Healthcare Conference have rallied investors’ confidence in the company’s mid-term prospects. 11 January 2023
Biotechnology
Another chapter in the long-running immunotherapy patent dispute between Bristol Myers Squibb and Gilead Sciences has been written. 10 January 2023
Biotechnology
After an active M&A year in 2022, UK pharma major AstraZeneca kicked off 2023 with an agreement to acquire USA-based clinical stage biotech CinCor Pharma. 9 January 2023
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze